Purchase by Joseph Vazzano of 2986 shares of Abeona Therapeutics

ABEO Stock  USD 5.50  0.28  4.84%   
About 50% of Abeona Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Abeona Therapeutics suggests that some traders are interested. Abeona Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Abeona Therapeutics. Many technical investors use Abeona Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Abeona Therapeutics Inc officer. General open market or private purchase of non-derivative or derivative security

Read at macroaxis.com
Abeona insider trading alert for perchase of common stock by Joseph Vazzano, Chief Financial Officer, on 21st of February 2024. This event was filed by Abeona Therapeutics Inc with SEC on 2023-09-20. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Abeona Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Abeona Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Abeona Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Abeona Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Abeona Therapeutics Fundamental Analysis

We analyze Abeona Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abeona Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abeona Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Abeona Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Abeona Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Abeona Therapeutics stock to make a market-neutral strategy. Peer analysis of Abeona Therapeutics could also be used in its relative valuation, which is a method of valuing Abeona Therapeutics by comparing valuation metrics with similar companies.

Peers

Abeona Therapeutics Related Equities

AFMDAffimed NV   1.96   
0%
6.0%
BDTXBlack Diamond   0.46   
0%
1.0%
ANEBAnebulo Pharmaceuticals   0.79   
2.0%
0%
INZYInozyme Pharma   0.80   
2.0%
0%
CABACabaletta Bio   1.44   
4.0%
0%
ADAPAdaptimmune Therapeutics   1.79   
5.0%
0%
DAWNDay One   2.01   
6.0%
0%
LPTXLeap Therapeutics   2.04   
6.0%
0%
ATHAAthira Pharma   2.33   
7.0%
0%
ACADACADIA Pharmaceuticals   2.36   
7.0%
0%
FBIOFortress Biotech   3.09   
10.0%
0%
XFORX4 Pharmaceuticals   4.26   
14.0%
0%
RGNXRegenxbio   4.68   
15.0%
0%
PDSBPDS Biotechnology   5.22   
17.0%
0%
MREOMereo BioPharma   5.61   
18.0%
0%
CKPTCheckpoint Therapeutics   5.75   
19.0%
0%
TERNTerns Pharmaceuticals   6.98   
23.0%
0%
RVPHReviva Pharmaceuticals   7.01   
23.0%
0%
IVVDInvivyd   29.94   
100.0%
0%
When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.05)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.41)
Return On Equity
(2.10)
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.